Salix Pharmaceuticals ( SLXP)

Drug/indication: Xifaxan for hepatic encephalopathy

Approval decision date: March 24

Salix will bring Xifaxan in front of an FDA advisory panel on Feb. 23, which will recommend to the FDA whether the drug should be approved or not. As part of these proceedings, the FDA will post its review of Xifaxan on its web site on Feb. 19 or 22.

If you liked this article you might like

Ardelyx Has Big Potential

Ardelyx Has Big Potential

Biotech M&A Waking Up After Long Nap

Biotech M&A Waking Up After Long Nap

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

Here's Why XenoPort (XNPT) Stock is Continuing to Surge Today

Trending Tickers: XNPT, OLED, MON, TPUB

Trending Tickers: XNPT, OLED, MON, TPUB